Currently, the primary efficacy measures for antidepressant clinical trials predominantly assess changes in mood symptoms in patients with major depressive disorder (MDD). When considering treatment ...

Israeli biotechnology firm ElMindA – developers of the world’s first FDA-approved neural functional assessment tool to visualize serious brain trauma and illnesses – has been named one of the 49 most ...